Jia Yibin, Wang Nana, Wang Jianbo, Tian Hui, Ma Wei, Wang Kai, Tan Bingxu, Zhang Guangyu, Yang Shengsi, Bai Bing, Cheng Yufeng
Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, People's Republic of China.
Ann Surg Oncol. 2014 Jan;21(1):329-36. doi: 10.1245/s10434-013-3225-x. Epub 2013 Aug 28.
Recent studies have identified loss of stromal caveolin-1 (Cav-1) expression as a new prognostic histological characteristic in various types of human cancers. However, the clinical and pathological significance of stromal Cav-1 expression in esophageal squamous cell carcinoma (ESCC) remains largely unknown. We examined Cav-1 expression in both tumor and stromal cells in ESCC tissue by immunohistochemical analysis to evaluate its clinicopathological significance and prognostic value.
A total of 110 patients with ESCC who underwent surgical resection were included in this study. The expression of Cav-1 in both tumor and stromal cells in esophageal tumor tissues was examined immunohistochemically.
Cav-1 expression was found in the cytoplasm of both tumor and stromal cells. Tumor Cav-1 overexpression was observed in 37.3 % tumors, which correlated to deeper tumor invasion (p = 0.038). Down-regulation of stromal Cav-1 expression was observed in 40.9 % tumors. The stromal Cav-1 down-regulation group had more lymph node metastases and more locoregional recurrences than those with higher expression (p = 0.020 and p = 0.002, respectively). In addition, down-regulation of stromal Cav-1 expression was associated with shorter disease-free survival (p < 0.001) and overall survival (p < 0.001). Multivariate analysis revealed that down-regulation of stromal Cav-1 expression was an independent prognostic factor for both disease-free survival (p = 0.028) and overall survival (p = 0.007).
Down-regulation of stromal Cav-1 expression in ESCC had high malignant potential. It predicts high-risk of lymph node metastases and locoregional recurrence, and it could be a powerful prognostic marker for patients with ESCC.
最近的研究已确定基质小窝蛋白-1(Cav-1)表达缺失是多种人类癌症新的预后组织学特征。然而,基质Cav-1表达在食管鳞状细胞癌(ESCC)中的临床和病理意义仍 largely 未知。我们通过免疫组织化学分析检测 ESCC 组织中肿瘤细胞和基质细胞中 Cav-1 的表达,以评估其临床病理意义和预后价值。
本研究纳入了 110 例行手术切除的 ESCC 患者。采用免疫组织化学方法检测食管肿瘤组织中肿瘤细胞和基质细胞中 Cav-1 的表达。
在肿瘤细胞和基质细胞的细胞质中均发现 Cav-1 表达。37.3%的肿瘤中观察到肿瘤 Cav-1 过表达,这与肿瘤侵袭更深相关(p = 0.038)。40.9%的肿瘤中观察到基质 Cav-1 表达下调。基质 Cav-1 下调组比表达较高者有更多的淋巴结转移和更多的局部区域复发(分别为 p = 0.020 和 p = 0.002)。此外,基质 Cav-1 表达下调与无病生存期缩短(p < 0.001)和总生存期缩短(p < 0.001)相关。多因素分析显示,基质 Cav-1 表达下调是无病生存期(p = 0.028)和总生存期(p = 0.007)的独立预后因素。
ESCC 中基质 Cav-1 表达下调具有高恶性潜能。它预示着淋巴结转移和局部区域复发的高风险,并且可能是 ESCC 患者的一个有力预后标志物。